Search results
Showing 316 to 330 of 1050 results for drug therapy
Oesophago-gastric cancer: assessment and management in adults (NG83)
This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support. It aims to reduce variation in practice through better organisation of care and support, and improve quality of life and survival by giving advice on the most suitable treatments depending on cancer type, stage and location.
NICE has developed a medtech innovation briefing (MIB) on CytoSorb therapy for sepsis .
This quality standard covers the care of adults (aged 18 and over) with suspected or confirmed acute heart failure. It describes high-quality care in priority areas for improvement.
View quality statements for QS103Show all sections
Sections for QS103
- Quality statements
- Quality statement 1: Single measurement of natriuretic peptide
- Quality statement 2: Transthoracic doppler 2D echocardiography
- Quality statement 3: Organisation of care – early specialist input
- Quality statement 4: Starting or continuing beta-blocker treatment
- Quality statement 5: Drug therapy
- Quality statement 6: Follow-up clinical assessment
- About this quality standard
Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults.
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies.
The NICE glossary provides brief definitions and explanations of terms used on the website. The terms describe how NICE works and how its guidance is produced.
Sarilumab for moderate to severe rheumatoid arthritis (TA485)
Evidence-based recommendations on sarilumab (Kevzara) for treating moderate to severe rheumatoid arthritis in adults.
Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic, hormone-relapsed prostate cancer for people in whom chemotherapy is not yet clinically indicated.
Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making
Summary of the evidence on antimicrobial prescribing: delafloxacin
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine, in adults.
Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)
Evidence-based recommendations on lenvatinib (Lenvima) for untreated advanced hepatocellular carcinoma in adults.
Evidence-based recommendations on cinacalcet (Mimpara) for treating secondary hyperparathyroidism in people with end-stage renal disease who are on dialysis.
MRI-guided focused ultrasound subthalamotomy for treating Parkinson's (HTG734)
Evidence-based recommendations on MRI-guided focused ultrasound subthalamotomy for treating Parkinson’s. This involves using ultrasound to destroy tissue in an area of the brain linked to Parkinson’s symptoms.
View recommendations for HTG734Show all sections
Evidence-based recommendations on MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson’s. This involves using ultrasound to destroy tissue in the thalamus.